Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Pegging the interferon data

Schering-Plough Corp. (SGP, Madison, N.J.) has its PEG-Intron peginterferon alfa-2b under regulatory review in the U.S. and Europe to treat hepatitis C, while Hoffmann-La Roche Inc. (Nutley, N.J.) has its Pegasys peginterferon alfa-2a in Phase III testing. While the absolute numbers for virologic response in the Phase III data suggest that Pegasys may have greater efficacy, PEG-Intron, which uses polyethylene glycol (PEG) technology licensed from Enzon

Read the full 667 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE